• 简

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    How Agilent’s New GMP-Ready xCELLigence Software Could Reshape Agilent Technologies (A) Investors’ Outlook

    Simply Wall St·12/15/2025 05:10:46
    语音播报
    • Earlier this month, Agilent Technologies released new 21 CFR Part 11 compliance software for its xCELLigence RTCA eSight system, adding secure user authentication, electronic signatures, and full audit trails so the live-cell analysis platform can be used in GMP-regulated manufacturing and quality control as well as research and development labs.
    • This upgrade extends the same real-time cell analysis platform across the pharma and biopharma value chain, aligning with growing demand for regulatory-ready digital lab tools in biopharma and cell therapy manufacturing where data integrity and audit-readiness are essential.
    • We’ll now explore how extending xCELLigence RTCA eSight into GMP-regulated settings could reshape Agilent’s investment narrative and growth profile.

    These 10 companies survived and thrived after COVID and have the right ingredients to survive Trump's tariffs. Discover why before your portfolio feels the trade war pinch.

    Agilent Technologies Investment Narrative Recap

    To own Agilent, you need to believe its core strength in high quality analytical instruments and growing software and services can offset tariff pressure, softer academic funding, and rising competition. The new 21 CFR Part 11 software for xCELLigence eSight supports that thesis at the margin by nudging more of its live cell analysis franchise into regulated, higher value pharma workflows, but it does not meaningfully change the near term risk that rising tariff driven costs could still weigh on margins if mitigation slips.

    The recent Q4 2025 results, with full year revenue of US$6,948.0 million and net income of US$1,303.0 million, provide the clearest backdrop for this product news, since they show how much room Agilent has to absorb incremental investment in software heavy offerings while still focusing on margin discipline. Seeing how this compliance ready xCELLigence expansion fits alongside the company’s broader push into recurring software and services is key to judging its role in the story.

    Yet despite these positives, investors should be aware that tariff driven cost inflation and supply chain reshoring could still...

    Read the full narrative on Agilent Technologies (it's free!)

    Agilent Technologies' narrative projects $8.0 billion revenue and $1.7 billion earnings by 2028. This requires 5.8% yearly revenue growth and an earnings increase of about $0.5 billion from $1.2 billion today.

    Uncover how Agilent Technologies' forecasts yield a $169.44 fair value, a 21% upside to its current price.

    Exploring Other Perspectives

    A 1-Year Stock Price Chart
    A 1-Year Stock Price Chart

    Five Simply Wall St Community fair value estimates for Agilent span roughly US$114.71 to US$169.44, underlining how far apart individual views can be. Set this against the current concern that higher global tariffs and supply chain complexity may pressure margins, and you can see why it pays to compare several of these perspectives before deciding how you think Agilent’s story plays out.

    Explore 5 other fair value estimates on Agilent Technologies - why the stock might be worth as much as 21% more than the current price!

    Build Your Own Agilent Technologies Narrative

    Disagree with existing narratives? Create your own in under 3 minutes - extraordinary investment returns rarely come from following the herd.

    • A great starting point for your Agilent Technologies research is our analysis highlighting 4 key rewards that could impact your investment decision.
    • Our free Agilent Technologies research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Agilent Technologies' overall financial health at a glance.

    No Opportunity In Agilent Technologies?

    Early movers are already taking notice. See the stocks they're targeting before they've flown the coop:

    This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.